The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Publications hub
Find our publications, laboratory reports, meeting minutes and statements, and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
-
search our Resources
-
use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Advertising (24)
- (-) Listed medicines (7)
- Advisory bodies and committees (358)
- Scheduling (national classification system) (155)
- Prescription medicines (34)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (22)
- Therapeutic goods regulation (19)
- Medical devices safety (13)
- Manufacturing (11)
- Safety (11)
- Complementary medicines (9)
- Non-prescription medicines (9)
- Over the counter (OTC) medicines (8)
- Regulatory compliance (8)
- COVID-19 vaccines (7)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Registered complementary medicines (6)
- Assessed listed medicines (5)
- Shortages (4)
- Alert/Advisory (3)
- Fees and payments (3)
- Legislation (3)
- Clinical trials (2)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
31 result(s) found, displaying 1 to 25
-
PublicationsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Meeting statementsCommunique from the meeting of the TGACC
-
PublicationsThe strategy outlines the approach we will use to identify, engage with, and educate stakeholders about regulatory requirements and our compliance outcomes.
-
Meeting statementsCommunique from the meeting of the TGACC
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Meeting statementsCommunique from the meeting of the TGACC
-
PublicationsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 17 August 2022.
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 23 August 2021.
-
PublicationsOutcomes following review of consultation submissions
-
PublicationsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 31 March 2021
-
PublicationsThe Australian Government has accepted all 22 recommendations
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 19 November 2020
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Meeting statementsA meeting of the TGACC was held on 27 August 2020. A communique has been published.
-
PublicationsFinal Report on the impact of advertising reforms from the Expert Panel Review of Medicines and Medical Devices Regulation, and other initiatives
-
PublicationsThe independent review is complete and the report now published.
-
Meeting statementsCommunique from the meeting of the TGACC
-
PublicationsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
Meeting statementsThe TGACC meeting was held on 20 Feb 2020, a communique has been published
-
PublicationsThe TGA has conducted a safety review on coumarin in topical listed medicines
-
Meeting statementsCommunique from the fourth meeting of the TGACC